SpringerLink
Log in

The Role of fMRI in Drug Development: An Update

  • Chapter
  • First Online:
Drug Development in Psychiatry

Part of the book series: Advances in Neurobiology ((NEUROBIOL,volume 30))

Abstract

Functional magnetic resonance imaging (fMRI) of the brain is a technology that holds great potential for increasing the efficiency of drug development for the central nervous system (CNS). In preclinical studies and both early- and late-phase human trials, fMRI has the potential to improve cross-species translation of drug effects, help to de-risk compounds early in development, and contribute to the portfolio of evidence for a compound’s efficacy and mechanism of action. However, to date, the utilization of fMRI in the CNS drug development process has been limited. The purpose of this chapter is to explore this mismatch between potential and utilization. This chapter provides introductory material related to fMRI and drug development, describes what is required of fMRI measurements for them to be useful in a drug development setting, lists current capabilities of fMRI in this setting and challenges faced in its utilization, and ends with directions for future development of capabilities in this arena. This chapter is the 5-year update of material from a previously published workshop summary (Carmichael et al., Drug DiscovToday 23(2):333–348, 2018).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Avila AM, Bebenek I, Bonzo JA, Bourcier T, Davis Bruno KL, Carlson DB, et al. An FDA/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol. 2020;114:104662.

    Article  CAS  PubMed  Google Scholar 

  2. Suhara T, Chaki S, Kimura H, Furusawa M, Matsumoto M, Ogura H, et al. Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development: CINP/JSNP Working Group report. Int J Neuropsychopharmacol. 2017;20(4):285–94.

    CAS  PubMed  Google Scholar 

  3. van der Doef TF, Zaragoza Domingo S, Jacobs GE, Drevets WC, Marston HM, Nathan PJ, et al. New approaches in psychiatric drug development. Eur Neuropsychopharmacol. 2018;28(9):983–93.

    Article  PubMed  Google Scholar 

  4. Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol. 2020;16(7):381–400.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Khalili-Mahani N, Rombouts SA, van Osch MJ, Duff EP, Carbonell F, Nickerson LD, et al. Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: a review of state-of-the-Art, challenges, and opportunities for studying brain chemistry. Hum Brain Mapp. 2017;38(4):2276–325.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Smith SM, Dworkin RH, Turk DC, Baron R, Polydefkis M, Tracey I, et al. The potential role of sensory testing, skin biopsy, and functional brain imaging as biomarkers in chronic pain clinical trials: IMMPACT considerations. J Pain. 2017;18(7):757–77.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Papanastasiou E, Shergill SS. Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? J Psychopharmacol. 2021;35(9):1158–60.

    Article  PubMed  PubMed Central  Google Scholar 

  8. De Stefano N, Giorgio A. Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials – commentary. Mult Scler. 2017;23(11):1458–60.

    Article  PubMed  Google Scholar 

  9. Diaz-Caneja CM, State MW, Hagerman RJ, Jacquemont S, Marin O, Bagni C, et al. A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. Eur Neuropsychopharmacol. 2021;48:49–88.

    Article  CAS  PubMed  Google Scholar 

  10. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development# 1: processes and requirements. Drug Discov Today. 2011;16(13):583–93.

    Article  PubMed  Google Scholar 

  11. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development# 2: protocol optimization and best practices. Drug Discov Today. 2011;16(15):671–82.

    Article  PubMed  Google Scholar 

  12. Carmichael O, Schwarz AJ, Chatham CH, Scott D, Turner JA, Upadhyay J, et al. The role of fMRI in drug development. Drug Discov Today. 2018;23(2):333–48.

    Article  CAS  PubMed  Google Scholar 

  13. Logothetis NK, Pfeuffer J. On the nature of the BOLD fMRI contrast mechanism. Magn Reson Imaging. 2004;22(10):1517–31.

    Article  PubMed  Google Scholar 

  14. Logothetis NK, Wandell BA. Interpreting the BOLD signal. Annu Rev Physiol. 2004;66:735–69.

    Article  CAS  PubMed  Google Scholar 

  15. Petersen ET, Zimine I, Ho YC, Golay X. Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques. Br J Radiol. 2006;79(944):688–701.

    Article  CAS  PubMed  Google Scholar 

  16. van den Heuvel MP, Hulshoff Pol HE. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur Neuropsychopharmacol. 2010;20(8):519–34.

    Article  PubMed  Google Scholar 

  17. Wandschneider B, Koepp MJ. Pharmaco fMRI: determining the functional anatomy of the effects of medication. Neuroimage Clin. 2016;12:691–7.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Yang J, Gohel S, Vachha B. Current methods and new directions in resting state fMRI. Clin Imaging. 2020;65:47–53.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008;33(9):2080–92.

    Article  CAS  PubMed  Google Scholar 

  20. Wong EH, Yocca F, Smith MA, Lee C-M. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters’ perspective. Int J Neuropsychopharmacol. 2010;13(9):1269–84.

    Article  PubMed  Google Scholar 

  21. Perez-Caballero L, Torres-Sanchez S, Bravo L, Mico JA, Berrocoso E. Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Discovery. 2014;9(5):567–78.

    Article  CAS  Google Scholar 

  22. Goineau S, Lemaire M, Froget G. Overview of safety pharmacology. In: Current protocols in pharmacology. Hoboken: John Wiley & Sons, Inc.; 2001.

    Google Scholar 

  23. Gunn RN, Rabiner EA, editors. Imaging in central nervous system drug discovery. In: Seminars in nuclear medicine. Cambridge: Elsevier; 2017.

    Google Scholar 

  24. Combes R, Berridge T, Connelly J, Eve M, Garner R, Toon S, et al. Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci. 2003;19(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  25. LoRusso PM. Phase 0 clinical trials: an answer to drug development stagnation? J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(16):2586–8.

    Article  CAS  Google Scholar 

  26. Hansen AR, Graham DM, Pond GR, Siu LL. Phase 1 trial design: is 3 + 3 the best? Cancer Control. 2014;21(3):200–8.

    Article  PubMed  Google Scholar 

  27. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708–20.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Cook N, Hansen AR, Siu LL, Abdul Razak AR. Early phase clinical trials to identify optimal dosing and safety. Mol Oncol. 2015;9(5):997–1007.

    Article  CAS  PubMed  Google Scholar 

  29. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol. 2000;40(8):803–14.

    Article  CAS  PubMed  Google Scholar 

  30. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.

    Article  Google Scholar 

  31. Arneric SP, Kern VD, Stephenson DT. Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments. Biochem Pharmacol. 2018;151:291–306.

    Article  CAS  PubMed  Google Scholar 

  32. McGonigle P. Animal models of CNS disorders. Biochem Pharmacol. 2014;87(1):140–9.

    Article  CAS  PubMed  Google Scholar 

  33. Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther. 2009;329(2):404–11.

    Article  CAS  PubMed  Google Scholar 

  34. Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord. 2011;1:9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology. 2008;34(1):74–89.

    Article  PubMed  Google Scholar 

  36. Kaffman A, White JD, Wei L, Johnson FK, Krystal JH. Enhancing the utility of preclinical research in neuropsychiatry drug development. Methods Mol Biol. 2011;2019:3–22.

    Google Scholar 

  37. Zerbi V, Markicevic M, Gasparini F, Schroeter A, Rudin M, Wenderoth N. Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice. Neuroimage. 2019;191:392–402.

    Article  CAS  PubMed  Google Scholar 

  38. Li J, Yang R, **a K, Wang T, Nie B, Gao K, et al. Effects of stress on behavior and resting-state fMRI in rats and evaluation of Telmisartan therapy in a stress-induced depression model. BMC Psychiatry. 2018;18(1):337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Paasonen J, Salo RA, Ihalainen J, Leikas JV, Savolainen K, Lehtonen M, et al. Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat. Neuropharmacology. 2017;119:15–25.

    Article  CAS  PubMed  Google Scholar 

  40. Paasonen J. Optimization and implementation of preclinical pharmacologic fMRI for drug research and development. Dissertation. Itä-Suomen yliopisto; 2017.

    Google Scholar 

  41. English BA, Thomas K, Johnstone J, Bazih A, Gertsik L, Ereshefsky L. Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. Biomark Med. 2014;8(1):29–49.

    Article  CAS  PubMed  Google Scholar 

  42. Wilson FJ, Leiser SC, Ivarsson M, Christensen SR, Bastlund JF. Can pharmaco-electroencephalography help improve survival of central nervous system drugs in early clinical development? Drug Discov Today. 2014;19(3):282–8.

    Article  CAS  PubMed  Google Scholar 

  43. Borsook D, Becerra L, Fava M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry. 2013;3:e282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hargreaves RJ, Hoppin J, Sevigny J, Patel S, Chiao P, Klimas M, et al. Optimizing central nervous system drug development using molecular imaging. Clin Pharmacol Ther. 2015;98(1):47–60.

    Article  CAS  PubMed  Google Scholar 

  45. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 2009;34(1):187–203.

    Article  CAS  PubMed  Google Scholar 

  46. Nathan PJ, Phan KL, Harmer CJ, Mehta MA, Bullmore ET. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr Opin Pharmacol. 2014;14:54–61.

    Article  CAS  PubMed  Google Scholar 

  47. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry. 2005;62(3):282–8.

    Article  CAS  PubMed  Google Scholar 

  48. Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Schwarz AJ, Pendse G, et al. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. Neuroimage. 2012;59(4):3762–73.

    Article  CAS  PubMed  Google Scholar 

  49. Miller B, Marks LA, Koller JM, Newman BJ, Bretthorst GL, Black KJ. Prolactin and fMRI response to SKF38393 in the baboon. PeerJ. 2013;1:e195.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Borsook D, Upadhyay J, Hargreaves R, Wager T. Enhancing choice and outcomes for therapeutic trials in chronic pain: N-of-1 + Imaging (+ i). Trends Pharmacol Sci. 2020;41(2):85–98.

    Article  CAS  PubMed  Google Scholar 

  51. Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2019;18(1):82–4.

    Article  CAS  Google Scholar 

  52. Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. Nat Med. 2020;26(5):760–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Gandhi KD, Mansukhani MP, Karpyak VM, Schneekloth TD, Wang Z, Kolla BP. The impact of varenicline on alcohol consumption in subjects with alcohol use disorders: systematic review and meta-analyses. J Clin Psychiatry. 2020;81(2):19r12924.

    Article  PubMed  Google Scholar 

  54. Cannella N, Ubaldi M, Masi A, Bramucci M, Roberto M, Bifone A, et al. Building better strategies to develop new medications in Alcohol Use Disorder: learning from past success and failure to shape a brighter future. Neurosci Biobehav Rev. 2019;103:384–98.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Cummings J, Zhong K, Cordes D. Drug development in Alzheimer’s disease: the role of default mode network assessment in phase II. US Neurol. 2017;13(2):67–9.

    Article  Google Scholar 

  56. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov. 2009;8(12):949–57.

    Article  CAS  PubMed  Google Scholar 

  57. Sadraee A, Paulus M, Ekhtiari H. fMRI as an outcome measure in clinical trials: a systematic review in clinicaltrials.gov. Brain Behav. 2021;11(5):e02089.

    Article  PubMed  PubMed Central  Google Scholar 

  58. EMA. European Medicines Agency website 2016. Available from: http://www.ema.europa.eu/ema/

  59. FDA. Food and Drug Administration website 2016. Available from: https://www.fda.gov

  60. FDA. Food and Drug Administration: development & approval process (drugs) 2016. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm

  61. EMA. European Medicines Agency: scientific guidelines 2016. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000043.jsp&mid=WC0b01ac05800240cb

  62. EMA. European Medicines Agency: qualification of novel methodologies for medicine development 2016. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp

  63. FDA. Food and Drug Administration: drug development tools (DDT) qualification programs 2016. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm

  64. FDA. Food and Drug Administration: biomarker qualification program 2016. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm20086360.htm

  65. FDA. Qualification of biomarker-total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease; guidance for industry; availability. Federal Register: Food and Drug Administration; 2016.

    Google Scholar 

  66. Wise RG, Williams P, Tracey I. Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology. 2004;29(3):626.

    Article  CAS  PubMed  Google Scholar 

  67. Schweinhardt P, Bountra C, Tracey I. Pharmacological FMRI in the development of new analgesic compounds. NMR Biomed. 2006;19(6):702–11.

    Article  CAS  PubMed  Google Scholar 

  68. Oertel B, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, et al. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther. 2008;83(4):577–88.

    Article  CAS  PubMed  Google Scholar 

  69. De Simoni S, Schwarz AJ, O’Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test–retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75–90.

    Article  PubMed  Google Scholar 

  70. Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O’Daly OG, Williams SCR, Mehta MA. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther. 2013;345(1):151–60.

    Article  CAS  PubMed  Google Scholar 

  71. Clarke LP, Sriram RD, Schilling LB. Imaging as a biomarker: standards for change measurements in therapy workshop summary. Acad Radiol. 2008;15(4):501–30.

    Article  PubMed  Google Scholar 

  72. Kessler LG, Barnhart HX, Buckler AJ, Choudhury KR, Kondratovich MV, Toledano A, et al. The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions. Stat Methods Med Res. 2015;24(1):9–26.

    Article  PubMed  Google Scholar 

  73. Friedman L, Glover GH. Report on a multicenter fMRI quality assurance protocol. J Magn Reson Imaging. 2006;23(6):827–39.

    Article  PubMed  Google Scholar 

  74. Mitsis GD, Iannetti GD, Smart TS, Tracey I, Wise RG. Regions of interest analysis in pharmacological fMRI: how do the definition criteria influence the inferred result? Neuroimage. 2008;40(1):121–32.

    Article  PubMed  Google Scholar 

  75. Buck R, Singhal H, Arora J, Schlitt H, Constable RT. Detecting change in BOLD signal between sessions for atlas-based anatomical ROIs. Neuroimage. 2008;40(3):1157–65.

    Article  PubMed  Google Scholar 

  76. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685–91.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Van Essen DC, Ugurbil K, Auerbach E, Barch D, Behrens TE, Bucholz R, et al. The IMAGEN study: reinforcement-related behavior in normal brain function and pathology. Mol Psychiatry. 2010;15(12):1128–39.

    Article  Google Scholar 

  78. Van Essen DC, Ugurbil K, Auerbach E, Barch D, Behrens TE, Bucholz R, et al. The Human Connectome Project: a data acquisition perspective. Neuroimage. 2012;62(4):2222–31.

    Article  PubMed  Google Scholar 

  79. Chen JI, Ha B, Bushnell MC, Pike B, Duncan GH. Differentiating noxious- and innocuous-related activation of human somatosensory cortices using temporal analysis of fMRI. J Neurophysiol. 2002;88(1):464–74.

    Article  PubMed  Google Scholar 

  80. Glover GH, Mueller BA, Turner JA, van Erp TG, Liu TT, Greve DN, et al. Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. J Magn Reson Imaging. 2012;36(1):39–54.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Friedman L, Glover GH, Krenz D, Magnotta V, First B. Reducing inter-scanner variability of activation in a multicenter fMRI study: role of smoothness equalization. Neuroimage. 2006;32(4):1656–68.

    Article  PubMed  Google Scholar 

  82. Browne RH. On the use of a pilot sample for sample size determination. Stat Med. 1995;14(17):1933–40.

    Article  CAS  PubMed  Google Scholar 

  83. Van Dijk KR, Hedden T, Venkataraman A, Evans KC, Lazar SW, Buckner RL. Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization. J Neurophysiol. 2010;103(1):297–321.

    Article  PubMed  Google Scholar 

  84. Hutton C, Bork A, Josephs O, Deichmann R, Ashburner J, Turner R. Image distortion correction in fMRI: a quantitative evaluation. Neuroimage. 2002;16(1):217–40.

    Article  PubMed  Google Scholar 

  85. De Zwart JA, Ledden PJ, van Gelderen P, Bodurka J, Chu R, Duyn JH. Signal-to-noise ratio and parallel imaging performance of a 16-channel receive-only brain coil array at 3.0 Tesla. Magn Reson Med. 2004;51(1):22–6.

    Article  PubMed  Google Scholar 

  86. Pruessmann KP, Weiger M, Scheidegger MB, Boesiger P. SENSE: sensitivity encoding for fast MRI. Magn Reson Med. 1999;42(5):952–62.

    Article  CAS  PubMed  Google Scholar 

  87. Nagy Z, Weiskopf N. Efficient fat suppression by slice-selection gradient reversal in twice-refocused diffusion encoding. Magn Reson Med. 2008;60(5):1256–60.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Smith SM, Vidaurre D, Beckmann CF, Glasser MF, Jenkinson M, Miller KL, et al. Functional connectomics from resting-state fMRI. Trends Cogn Sci. 2013;17(12):666–82.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Larkman DJ, Hajnal JV, Herlihy AH, Coutts GA, Young IR, Ehnholm G. Use of multicoil arrays for separation of signal from multiple slices simultaneously excited. J Magn Reson Imaging. 2001;13(2):313–7.

    Article  CAS  PubMed  Google Scholar 

  90. Stocker T, Schneider F, Klein M, Habel U, Kellermann T, Zilles K, et al. Automated quality assurance routines for fMRI data applied to a multicenter study. Hum Brain Mapp. 2005;25(2):237–46.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Power JD, Mitra A, Laumann TO, Snyder AZ, Schlaggar BL, Petersen SE. Methods to detect, characterize, and remove motion artifact in resting state fMRI. Neuroimage. 2014;84:320–41.

    Article  PubMed  Google Scholar 

  92. Grodin EN, Ray LA. The use of functional magnetic resonance imaging to test pharmacotherapies for alcohol use disorder: a systematic review. Alcohol Clin Exp Res. 2019;43(10):2038–56.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Mahajan KR, Ontaneda D. The role of advanced magnetic resonance imaging techniques in multiple sclerosis clinical trials. Neurotherapeutics. 2017;14(4):905–23.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Sormani MP, Pardini M. Assessing repair in multiple sclerosis: outcomes for phase II clinical trials. Neurotherapeutics. 2017;14(4):924–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacology. 2019;44(2):259–73.

    Article  PubMed  Google Scholar 

  96. **ao F, Koepp MJ, Zhou D. Pharmaco-fMRI: a tool to predict the response to antiepileptic drugs in epilepsy. Front Neurol. 2019;10:1203.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Duff EP, Vennart W, Wise RG, Howard MA, Harris RE, Lee M, et al. Learning to identify CNS drug action and efficacy using multistudy fMRI data. Sci Transl Med. 2015;7(274):274ra16.

    Article  CAS  PubMed  Google Scholar 

  98. Liu CH, Greve DN, Dai G, Marota JJ, Mandeville JB. Remifentanil administration reveals biphasic phMRI temporal responses in rat consistent with dynamic receptor regulation. Neuroimage. 2007;34(3):1042–53.

    Article  PubMed  Google Scholar 

  99. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E. An fMRI-based neurologic signature of physical pain. N Engl J Med. 2013;368(15):1388–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Upadhyay J, Anderson J, Schwarz AJ, Coimbra A, Baumgartner R, Pendse G, et al. Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology. 2011;36(13):2659–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Gear R, Becerra L, Upadhyay J, Bishop J, Wallin D, Pendse G, et al. Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI. PLoS One. 2013;8(1):e50169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Elman I, Zubieta JK, Borsook D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. Arch Gen Psychiatry. 2011;68(1):12–20.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, et al. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci. 2012;15(8):1117–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Maleki N, Linnman C, Brawn J, Burstein R, Becerra L, Borsook D. Her versus his migraine: multiple sex differences in brain function and structure. Brain. 2012;135(Pt 8):2546–59.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Napadow V, Kim J, Clauw DJ, Harris RE. Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia. Arthritis Rheum. 2012;64(7):2398–403.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Kulkarni B, Bentley DE, Elliott R, Julyan PJ, Boger E, Watson A, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum. 2007;56(4):1345–54.

    Article  CAS  PubMed  Google Scholar 

  107. Xu A, Larsen B, Baller EB, Scott JC, Sharma V, Adebimpe A, et al. Convergent neural representations of experimentally-induced acute pain in healthy volunteers: a large-scale fMRI meta-analysis. Neurosci Biobehav Rev. 2020;112:300–23.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65(2):154–64.

    Article  PubMed  Google Scholar 

  109. Joules R, Doyle OM, Schwarz AJ, O’Daly OG, Brammer M, Williams SC, et al. Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile. Psychopharmacology (Berl). 2015;232(21-22):4205–18.

    Article  CAS  PubMed  Google Scholar 

  110. Yu H, Li Q, Wang D, Shi L, Lu G, Sun L, et al. Map** the central effects of chronic ketamine administration in an adolescent primate model by functional magnetic resonance imaging (fMRI). Neurotoxicology. 2012;33(1):70–7.

    Article  PubMed  Google Scholar 

  111. Corlett PR, Honey GD, Krystal JH, Fletcher PC. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology. 2011;36(1):294–315.

    Article  CAS  PubMed  Google Scholar 

  112. Krystal JH, Abi-Saab W, Perry E, D’Souza DC, Liu N, Gueorguieva R, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl). 2005;179(1):303–9.

    Article  CAS  PubMed  Google Scholar 

  113. Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol. 2007;21(3):283–301.

    Article  CAS  PubMed  Google Scholar 

  114. Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, et al. Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther. 2011;336(3):709–15.

    Article  CAS  PubMed  Google Scholar 

  115. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology. 2008;33(7):1690–703.

    Article  CAS  PubMed  Google Scholar 

  116. Haaf M, Leicht G, Curic S, Mulert C. Glutamatergic deficits in schizophrenia – biomarkers and pharmacological interventions within the ketamine model. Curr Pharm Biotechnol. 2018;19(4):293–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P. Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord. 2011;130(1-2):66–74.

    Article  CAS  PubMed  Google Scholar 

  118. van Wingen GA, Tendolkar I, Urner M, van Marle HJ, Denys D, Verkes RJ, et al. Short-term antidepressant administration reduces default mode and task-positive network connectivity in healthy individuals during rest. Neuroimage. 2013;88C:47–53.

    Google Scholar 

  119. Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, et al. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiat. 2015;72(1):5–13.

    Article  Google Scholar 

  120. Risacher SL, Wang Y, Wishart HA, Rabin LA, Flashman LA, McDonald BC, et al. Cholinergic enhancement of brain activation in mild cognitive impairment during episodic memory encoding. Front Psychiatry. 2013;4:105.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, et al. Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;19(3):591–611.

    Article  CAS  PubMed  Google Scholar 

  122. Stein EA, Pankiewicz J, Harsch HH, Cho JK, Fuller SA, Hoffmann RG, et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry. 1998;155(8):1009–15.

    Article  CAS  PubMed  Google Scholar 

  123. Hooker BA, Tobon G, Baker SJ, Zhu C, Hesterman J, Schmidt K, et al. Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain. Eur J Pain. 2014;18(2):223–37.

    Article  CAS  PubMed  Google Scholar 

  124. Governo RJ, Morris PG, Marsden CA, Chapman V. Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study. Br J Pharmacol. 2008;153(7):1558–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Upadhyay J, Baker SJ, Rajagovindan R, Hart M, Chandran P, Hooker BA, et al. Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. Neuroimage. 2013;64:341–55.

    Article  CAS  PubMed  Google Scholar 

  126. Kocsis P, Gyertyan I, Eles J, Laszy J, Hegedus N, Gajari D, et al. Vascular action as the primary mechanism of cognitive effects of cholinergic, CNS-acting drugs, a rat phMRI BOLD study. J Cereb Blood Flow Metab. 2014;34(6):995–1000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, et al. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology. 2014;39(7):1578–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Baker S, Chin CL, Basso AM, Fox GB, Marek GJ, Day M. Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection. J Pharmacol Exp Ther. 2012;341(1):263–73.

    Article  CAS  PubMed  Google Scholar 

  129. Rech J, Hess A, Finzel S, Kreitz S, Sergeeva M, Englbrecht M, et al. Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis. Arthritis Rheum. 2013;65(2):325–33.

    Article  CAS  PubMed  Google Scholar 

  130. Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, et al. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology. 2020;45(8):1339–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Bruns A, Mueggler T, Kunnecke B, Risterucci C, Prinssen EP, Wettstein JG, et al. “Domain gauges”: a reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats. Neuroimage. 2015;112:70–85.

    Article  CAS  PubMed  Google Scholar 

  132. Harris RE, Napadow V, Huggins JP, Pauer L, Kim J, Hampson J, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology. 2013;119(6):1453–64.

    Article  CAS  PubMed  Google Scholar 

  133. Sanders D, Krause K, O’Muircheartaigh J, Thacker MA, Huggins JP, Vennart W, et al. Pharmacologic modulation of hand pain in osteoarthritis: a double-blind placebo-controlled functional magnetic resonance imaging study using naproxen. Arthritis Rheumatol. 2015;67(3):741–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Becerra L, Schwartzman RJ, Kiefer RT, Rohr P, Moulton EA, Wallin D, et al. CNS measures of pain responses pre- and post-anesthetic ketamine in a patient with complex regional pain syndrome. Pain Med 2015;16(12):2368–85.

    Google Scholar 

  135. Wanigasekera V, Mezue M, Andersson J, Kong Y, Tracey I. Disambiguating pharmacodynamic efficacy from behavior with neuroimaging: implications for analgesic drug development. Anesthesiology. 2016;124(1):159–68.

    Article  CAS  PubMed  Google Scholar 

  136. Flodin P, Martinsen S, Altawil R, Waldheim E, Lampa J, Kosek E, et al. Intrinsic brain connectivity in chronic pain: a resting-state fMRI study in patients with rheumatoid arthritis. Front Hum Neurosci. 2016;10:107.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Petersen CS, Miskowiak KW. Toward a transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects: challenges, opportunities, and next steps. CNS Spectr. 2021;26(4):333–7.

    Article  PubMed  Google Scholar 

  138. Barron HC, Mars RB, Dupret D, Lerch JP, Sampaio-Baptista C. Cross-species neuroscience: closing the explanatory gap. Philos Trans R Soc Lond B Biol Sci. 2021;376(1815):20190633.

    Article  PubMed  Google Scholar 

  139. Robbins TW. Cross-species studies of cognition relevant to drug discovery: a translational approach. Br J Pharmacol. 2017;174(19):3191–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Francois J, Grimm O, Schwarz AJ, Schweiger J, Haller L, Risterucci C, et al. Ketamine suppresses the ventral striatal response to reward anticipation: a cross-species translational neuroimaging study. Neuropsychopharmacology. 2016;41(5):1386–94.

    Article  CAS  PubMed  Google Scholar 

  141. Becker R. Brain networks in pharmacological fMRI of NMDA antagonists. Dissertation. Heidelberg: Universitätsbibliothek Heidelberg; 2019.

    Google Scholar 

  142. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 1998;812(1-2):65–75.

    Article  CAS  PubMed  Google Scholar 

  143. Becerra L, Upadhyay J, Chang PC, Bishop J, Anderson J, Baumgartner R, et al. Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. J Pharmacol Exp Ther. 2013;345(1):41–51.

    Article  CAS  PubMed  Google Scholar 

  144. Grimm O, Gass N, Weber-Fahr W, Sartorius A, Schenker E, Spedding M, et al. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology (Berl). 2015;232(21-22):4231–41.

    Article  CAS  PubMed  Google Scholar 

  145. Masaki Y, Kashiwagi Y, Watabe H, Abe K. (R)- and (S)-ketamine induce differential fMRI responses in conscious rats. Synapse. 2019;73(12):e22126.

    Article  CAS  PubMed  Google Scholar 

  146. Masaki Y, Kashiwagi Y, Rokugawa T, Ito M, Iimori H, Abe K. Pharmacological MRI responses of raclopride in rats: The relationship with D2 receptor occupancy and cataleptic behavior. Synapse. 2020;74(12):e22180.

    Article  CAS  PubMed  Google Scholar 

  147. Gao L, Huang P, Dong Z, Gao T, Huang S, Zhou C, et al. Modified **aoyaosan (MXYS) exerts anti-depressive effects by rectifying the brain blood oxygen level-dependent fMRI signals and improving hippocampal neurogenesis in mice. Front Pharmacol. 2018;9:1098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Erb J, Armendariz M, De Martino F, Goebel R, Vanduffel W, Formisano E. Homology and specificity of natural sound-encoding in human and monkey auditory cortex. Cereb Cortex. 2019;29(9):3636–50.

    Article  PubMed  Google Scholar 

  149. Hori Y, Clery JC, Selvanayagam J, Schaeffer DJ, Johnston KD, Menon RS, et al. Interspecies activation correlations reveal functional correspondences between marmoset and human brain areas. Proc Natl Acad Sci U S A. 2021;118(37):e2110980118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Schaeffer DJ, Hori Y, Gilbert KM, Gati JS, Menon RS, Everling S. Divergence of rodent and primate medial frontal cortex functional connectivity. Proc Natl Acad Sci U S A. 2020;117(35):21681–9.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Specht K. Current challenges in translational and clinical fMRI and future directions. Front Psychiatry. 2019;10:924.

    Article  PubMed  Google Scholar 

  152. Gelman A, Loken E. The garden of forking paths: why multiple comparisons can be a problem, even when there is no “fishing expedition” or “p-hacking” and the research hypothesis was posited ahead of time. Department of Statistics, Columbia University; 2013.

    Google Scholar 

  153. Kriegeskorte N, Simmons WK, Bellgowan PS, Baker CI. Circular analysis in systems neuroscience: the dangers of double dip**. Nat Neurosci. 2009;12(5):535–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10(3):186–98.

    Article  CAS  PubMed  Google Scholar 

  155. Calhoun VD, Liu J, Adalı T. A review of group ICA for fMRI data and ICA for joint inference of imaging, genetic, and ERP data. Neuroimage. 2009;45(1):S163–S72.

    Article  PubMed  Google Scholar 

  156. Poldrack RA. Region of interest analysis for fMRI. Soc Cogn Affect Neurosci. 2007;2(1/4):67.

    Article  PubMed  PubMed Central  Google Scholar 

  157. Vatansever S, Schlessinger A, Wacker D, Kaniskan HU, ** J, Zhou MM, et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. Med Res Rev. 2021;41(3):1427–73.

    Article  PubMed  Google Scholar 

  158. Friedman L, Stern H, Brown GG, Mathalon DH, Turner J, Glover GH, et al. Test-retest and between-site reliability in a multicenter fMRI study. Hum Brain Mapp. 2008;29(8):958–72.

    Article  PubMed  Google Scholar 

  159. Harvey JL, Demetriou L, McGonigle J, Wall MB. A short, robust brain activation control task optimised for pharmacological fMRI studies. PeerJ. 2018;6:e5540.

    Article  PubMed  PubMed Central  Google Scholar 

  160. Upadhyay J, Lemme J, Anderson J, Bleakman D, Large T, Evelhoch JL, et al. Test-retest reliability of evoked heat stimulation BOLD fMRI. J Neurosci Methods. 2015;253:38–46.

    Article  PubMed  Google Scholar 

  161. Plichta MM, Schwarz AJ, Grimm O, Morgen K, Mier D, Haddad L, et al. Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery. Neuroimage. 2012;60(3):1746–58.

    Article  PubMed  Google Scholar 

  162. Kampa M, Schick A, Sebastian A, Wessa M, Tuscher O, Kalisch R, et al. Replication of fMRI group activations in the neuroimaging battery for the Mainz Resilience Project (MARP). Neuroimage. 2020;204:116223.

    Article  PubMed  Google Scholar 

  163. Holiga S, Sambataro F, Luzy C, Greig G, Sarkar N, Renken RJ, et al. Test-retest reliability of task-based and resting-state blood oxygen level dependence and cerebral blood flow measures. PLoS One. 2018;13(11):e0206583.

    Article  PubMed  PubMed Central  Google Scholar 

  164. Elliott ML, Knodt AR, Ireland D, Morris ML, Poulton R, Ramrakha S, et al. Poor test-retest reliability of task-fMRI: new empirical evidence and a meta-analysis. BioRxiv. 2019:681700.

    Google Scholar 

  165. Nord CL, Gray A, Charpentier CJ, Robinson OJ, Roiser JP. Unreliability of putative fMRI biomarkers during emotional face processing. Neuroimage. 2017;156:119–27.

    Article  CAS  PubMed  Google Scholar 

  166. Fiecas M, Ombao H, van Lunen D, Baumgartner R, Coimbra A, Feng D. Quantifying temporal correlations: a test-retest evaluation of functional connectivity in resting-state fMRI. Neuroimage. 2013;65:231–41.

    Article  PubMed  Google Scholar 

  167. Shehzad Z, Kelly AM, Reiss PT, Gee DG, Gotimer K, Uddin LQ, et al. The resting brain: unconstrained yet reliable. Cereb Cortex. 2009;19(10):2209–29.

    Article  PubMed  PubMed Central  Google Scholar 

  168. Baumgartner R, Cho W, Coimbra A, Chen C, Wang Z, Struyk A, et al. Evaluation of an fMRI USPIO-based assay in healthy human volunteers. J Magn Reson Imaging. 2017;46(1):124–33.

    Article  PubMed  Google Scholar 

  169. Petersson KM, Nichols TE, Poline JB, Holmes AP. Statistical limitations in functional neuroimaging. II. Signal detection and statistical inference. Philos Trans R Soc Lond B Biol Sci. 1999;354(1387):1261–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Henson R. What can functional neuroimaging tell the experimental psychologist? Q J Exp Psychol A. 2005;58(2):193–233.

    Article  PubMed  Google Scholar 

  171. Vul E, Harris C, Winkielman P, Pashler H. Puzzlingly high correlations in fmri studies of emotion, personality, and social cognition. Perspect Psychol Sci. 2009;4(3):274–90.

    Article  PubMed  Google Scholar 

  172. Yarkoni T. Big correlations in little studies: inflated fMRI correlations reflect low statistical power—commentary on Vul et al. (2009). Perspect Psychol Sci. 2009;4(3):294–8.

    Article  PubMed  Google Scholar 

  173. David SP, Ware JJ, Chu IM, Loftus PD, Fusar-Poli P, Radua J, et al. Potential reporting bias in fMRI studies of the brain. PLoS One. 2013;8(7):e70104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  175. Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, et al. Best practices in data analysis and sharing in neuroimaging using MRI. bioRxiv. 2016:054262.

    Google Scholar 

  176. Poldrack RA, Fletcher PC, Henson RN, Worsley KJ, Brett M, Nichols TE. Guidelines for reporting an fMRI study. Neuroimage. 2008;40(2):409–14.

    Article  PubMed  Google Scholar 

  177. Frohner JH, Teckentrup V, Smolka MN, Kroemer NB. Addressing the reliability fallacy in fMRI: similar group effects may arise from unreliable individual effects. Neuroimage. 2019;195:174–89.

    Article  PubMed  Google Scholar 

  178. Kragel PA, Han X, Kraynak TE, Gianaros PJ, Wager TD. Functional MRI can be highly reliable, but it depends on what you measure: a commentary on Elliott et al. (2020). Psychol Sci. 2021;32(4):622–6.

    Article  PubMed  PubMed Central  Google Scholar 

  179. Elliott ML, Knodt AR, Hariri AR. Striving toward translation: strategies for reliable fMRI measurement. Trends Cogn Sci. 2021;25(9):776–87.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Sheth SA, Nemoto M, Guiou M, Walker M, Pouratian N, Toga AW. Linear and nonlinear relationships between neuronal activity, oxygen metabolism, and hemodynamic responses. Neuron. 2004;42(2):347–55.

    Article  CAS  PubMed  Google Scholar 

  181. Zilles K, Mohlberg H, Amunts K, Palomero-Gallagher N, Bludau S. Cytoarchitecture and maps of the human cerebral cortex. Strukturelle und funktionelle Organisation des Gehirns; 2015. Report No.: 0123970253.

    Google Scholar 

  182. Amunts K, Zilles K. Advances in cytoarchitectonic map** of the human cerebral cortex. Neuroimaging Clin N Am. 2001;11(2):151–69, vii.

    CAS  PubMed  Google Scholar 

  183. Wohlschläger AM, Specht K, Lie C, Mohlberg H, Wohlschläger A, Bente K, et al. Linking retinotopic fMRI map** and anatomical probability maps of human occipital areas V1 and V2. Neuroimage. 2005;26(1):73–82.

    Article  PubMed  Google Scholar 

  184. Toga AW. Brain map**: an encyclopedic reference. London: Academic Press; 2015.

    Google Scholar 

  185. Ogawa S, Menon R, Tank D, Kim S, Merkle H, Ellermann J, et al. Functional brain map** by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J. 1993;64(3):803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Mathiesen C, Caesar K, Akgören N, Lauritzen M. Modification of activity-dependent increases of cerebral blood flow by excitatory synaptic activity and spikes in rat cerebellar cortex. J Physiol. 1998;512(2):555–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Shmuel A, Grinvald A. Functional organization for direction of motion and its relationship to orientation maps in cat area 18. J Neurosci. 1996;16(21):6945–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Smith AJ, Blumenfeld H, Behar KL, Rothman DL, Shulman RG, Hyder F. Cerebral energetics and spiking frequency: the neurophysiological basis of fMRI. Proc Natl Acad Sci. 2002;99(16):10765–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 2004;27(8):489–95.

    Article  CAS  PubMed  Google Scholar 

  190. Ances B, Vaida F, Ellis R, Buxton R. Test–retest stability of calibrated BOLD-fMRI in HIV− and HIV+ subjects. Neuroimage. 2011;54(3):2156–62.

    Article  PubMed  Google Scholar 

  191. Goodwin JA, Vidyasagar R, Balanos GM, Bulte D, Parkes LM. Quantitative fMRI using hyperoxia calibration: reproducibility during a cognitive Stroop task. Neuroimage. 2009;47(2):573–80.

    Article  PubMed  Google Scholar 

  192. Leontiev O, Buxton RB. Reproducibility of BOLD, perfusion, and CMRO 2 measurements with calibrated-BOLD fMRI. Neuroimage. 2007;35(1):175–84.

    Article  PubMed  Google Scholar 

  193. Wey H-Y, Wang DJ, Duong TQ. Baseline CBF, and BOLD, CBF, and CMRO2 fMRI of visual and vibrotactile stimulations in baboons. J Cereb Blood Flow Metab. 2011;31(2):715–24.

    Article  PubMed  Google Scholar 

  194. He X, Yablonskiy DA. Quantitative BOLD: map** of human cerebral deoxygenated blood volume and oxygen extraction fraction: default state. Magn Reson Med. 2007;57(1):115–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Lu H, Ge Y. Quantitative evaluation of oxygenation in venous vessels using T2-Relaxation-Under-Spin-Tagging MRI. Magn Reson Med. 2008;60(2):357–63.

    Article  PubMed  PubMed Central  Google Scholar 

  196. Bolar DS, Rosen BR, Sorensen A, Adalsteinsson E. QUantitative Imaging of eXtraction of oxygen and TIssue consumption (QUIXOTIC) using venular-targeted velocity-selective spin labeling. Magn Reson Med. 2011;66(6):1550–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  197. Yablonskiy DA, Sukstanskii AL, He X. Blood oxygenation level-dependent (BOLD)-based techniques for the quantification of brain hemodynamic and metabolic properties–theoretical models and experimental approaches. NMR Biomed. 2013;26(8):963–86.

    Article  CAS  PubMed  Google Scholar 

  198. Wehrl HF, Hossain M, Lankes K, Liu C-C, Bezrukov I, Martirosian P, et al. Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. 2013;19(9):1184–9.

    Article  CAS  PubMed  Google Scholar 

  199. Bruinsma TJ, Sarma VV, Oh Y, Jang DP, Chang SY, Worrell GA, et al. The relationship between dopamine neurotransmitter dynamics and the blood-oxygen-level-dependent (BOLD) signal: a review of pharmacological functional magnetic resonance imaging. Front Neurosci. 2018;12:238.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Mitsis GD, Governo RJ, Rogers R, Pattinson KT. The effect of remifentanil on respiratory variability, evaluated with dynamic modeling. J Appl Physiol (Bethesda, Md: 1985). 2009;106(4):1038–49.

    Article  CAS  Google Scholar 

  201. Khalili-Mahani N, Chang C, van Osch MJ, Veer IM, van Buchem MA, Dahan A, et al. The impact of “physiological correction” on functional connectivity analysis of pharmacological resting state fMRI. Neuroimage. 2013;65:499–510.

    Article  PubMed  Google Scholar 

  202. Ekhtiari H, Kuplicki R, Yeh HW, Paulus MP. Physical characteristics not psychological state or trait characteristics predict motion during resting state fMRI. Sci Rep. 2019;9(1):419.

    Article  PubMed  PubMed Central  Google Scholar 

  203. Olszowy W. Validation of statistical methods used in task fMRI studies. Dissertation. Cambridge: University of Cambridge; 2019.

    Google Scholar 

  204. Sirmpilatze N, Baudewig J, Boretius S. Temporal stability of fMRI in medetomidine-anesthetized rats. Sci Rep. 2019;9(1):16673.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Steiner AR, Rousseau-Blass F, Schroeter A, Hartnack S, Bettschart-Wolfensberger R. Systematic review: anaesthetic protocols and management as confounders in rodent blood oxygen level dependent functional magnetic resonance imaging (BOLD fMRI)-Part A: effects of changes in physiological parameters. Front Neurosci. 2020;14:577119.

    Article  PubMed  PubMed Central  Google Scholar 

  206. Steiner AR, Rousseau-Blass F, Schroeter A, Hartnack S, Bettschart-Wolfensberger R. Systematic review: anesthetic protocols and management as confounders in rodent blood oxygen level dependent functional magnetic resonance imaging (BOLD fMRI)-Part B: effects of anesthetic agents, doses and timing. Animals (Basel). 2021;11(1):199.

    Article  PubMed  Google Scholar 

  207. Sorger B, Scharnowski F, Linden DEJ, Hampson M, Young KD. Control freaks: towards optimal selection of control conditions for fMRI neurofeedback studies. Neuroimage. 2019;186:256–65.

    Article  PubMed  Google Scholar 

  208. Iannetti G, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging. 2007;25(6):978–88.

    Article  CAS  PubMed  Google Scholar 

  209. Walter SA, Forsgren M, Lundengård K, Simon R, Nilsson MT, Söderfeldt B, et al. Positive allosteric modulator of GABA lowers BOLD responses in the cingulate cortex. PLoS One. 2016;11(3):e0148737.

    Article  PubMed  PubMed Central  Google Scholar 

  210. Black KJ, Koller JM, Miller BD. Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle. PeerJ. 2013;1:e117.

    Article  PubMed  PubMed Central  Google Scholar 

  211. Koller JM, Vachon MJ, Bretthorst GL, Black KJ. Rapid quantitative pharmacodynamic imaging with Bayesian estimation. Front Neurosci. 2016;10:144.

    Article  PubMed  PubMed Central  Google Scholar 

  212. Mandeville JB, Sander CY, Jenkins BG, Hooker JM, Catana C, Vanduffel W, et al. A receptor-based model for dopamine-induced fMRI signal. Neuroimage. 2013;75:46–57.

    Article  CAS  PubMed  Google Scholar 

  213. Marota JJ, Mandeville JB, Weisskoff RM, Moskowitz MA, Rosen BR, Kosofsky BE. Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. Neuroimage. 2000;11(1):13–23.

    Article  CAS  PubMed  Google Scholar 

  214. Sidén P, Eklund A, Bolin D, Villani M. Fast Bayesian whole-brain fMRI analysis with spatial 3D priors. Neuroimage. 2017;146:211–25.

    Article  PubMed  Google Scholar 

  215. Borsook D, Upadhyay J, Klimas M, Schwarz AJ, Coimbra A, Baumgartner R, et al. Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. Drug Discov Today. 2012;17(17-18):964–73.

    Article  CAS  PubMed  Google Scholar 

  216. Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan P, et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011;16(8):826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Nathan PJ, O’neill BV, Bush MA, Koch A, Tao WX, Maltby K, et al. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist. J Clin Pharmacol. 2012;52(4):464–74.

    Article  CAS  PubMed  Google Scholar 

  218. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002;26(6):713–28.

    Article  CAS  PubMed  Google Scholar 

  219. Yeomans MR, Wright P. Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite. 1991;16(3):249–59.

    Article  CAS  PubMed  Google Scholar 

  220. Hirvonen J, Aalto S, Hagelberg N, Maksimow A, Ingman K, Oikonen V, et al. Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects. Eur J Nucl Med Mol Imaging. 2009;36(2):275–86.

    Article  CAS  PubMed  Google Scholar 

  221. Leppa M, Korvenoja A, Carlson S, Timonen P, Martinkauppi S, Ahonen J, et al. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage. 2006;31(2):661–9.

    Article  PubMed  Google Scholar 

  222. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg. 2006;103(1):208–16, table of contents.

    Article  CAS  PubMed  Google Scholar 

  223. Murdaugh DL, Cox JE, Cook EW, Weller RE. fMRI reactivity to high-calorie food pictures predicts short-and long-term outcome in a weight-loss program. Neuroimage. 2012;59(3):2709–21.

    Article  PubMed  Google Scholar 

  224. Etkin A, Maron-Katz A, Wu W, Fonzo GA, Huemer J, Vertes PE, et al. Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder. Sci Transl Med. 2019;11(486):eaal3236.

    Article  PubMed  PubMed Central  Google Scholar 

  225. Szaflarski JP, Gloss D, Binder JR, Gaillard WD, Golby AJ, Holland SK, et al. Practice guideline summary: use of fMRI in the presurgical evaluation of patients with epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2017;88(4):395–402.

    Article  PubMed  PubMed Central  Google Scholar 

  226. Tu Y, Zeng F, Lan L, Li Z, Maleki N, Liu B, et al. An fMRI-based neural marker for migraine without aura. Neurology. 2020;94(7):e741–e51.

    Article  PubMed  PubMed Central  Google Scholar 

  227. Loth E, Charman T, Mason L, Tillmann J, Jones EJH, Wooldridge C, et al. The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders. Mol Autism. 2017;8:24.

    Article  PubMed  PubMed Central  Google Scholar 

  228. Webb SJ, Shic F, Murias M, Sugar CA, Naples AJ, Barney E, et al. biomarker acquisition and quality control for multi-site studies: the Autism Biomarkers Consortium for clinical trials. Front Integr Neurosci. 2019;13:71.

    Article  PubMed  Google Scholar 

  229. Ness S, Pandina G, Jagannatha S, Wathen K, Bangerter A, Manyakov NV, et al. ASPI: a public-private partnership to develop treatments for autism. Nat Rev Drug Discov. 2020;19(4):219–20.

    Article  CAS  PubMed  Google Scholar 

  230. Koroshetz W, Gordon J, Adams A, Beckel-Mitchener A, Churchill J, Farber G, et al. The state of the NIH BRAIN initiative. J Neurosci. 2018;38(29):6427–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  231. Parekh A, Buckman-Garner S, McCune S, ONeill R, Geanacopoulos M, Amur S, et al. Catalyzing the critical path initiative: FDA’s progress in drug development activities. Clin Pharmacol Ther. 2015;97(3):221–33.

    Article  CAS  PubMed  Google Scholar 

  232. The National Academies of Sciences, Engineering, and Medicine. Advancing therapeutic development for pain and opioid use disorders through public-private partnerships: proceedings of a workshop. 2018.

    Google Scholar 

  233. Brady LS, Potter WZ, Gordon JA. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discov. 2019;14(12):1213–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  234. Bach P, Weil G, Pompili E, Hoffmann S, Hermann D, Vollstadt-Klein S, et al. FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. Eur Arch Psychiatry Clin Neurosci. 2021;271(5):915–27.

    Article  PubMed  PubMed Central  Google Scholar 

  235. Neville J, Kopko S, Romero K, Corrigan B, Stafford B, LeRoy E, et al. Accelerating drug development for Alzheimer’s disease through the use of data standards. Alzheimers Dement (N Y). 2017;3(2):273–83.

    Article  PubMed  Google Scholar 

  236. Spellman BA. Introduction to the special section data, data, everywhere... especially in my file drawer. Perspect Psychol Sci. 2012;7(1):58–9.

    Article  PubMed  Google Scholar 

  237. Eickhoff S, Nichols TE, Van Horn JD, Turner JA. Sharing the wealth: neuroimaging data repositories. Neuroimage. 2016;124(Pt B):1065–8.

    Article  PubMed  Google Scholar 

  238. The Research Domain Criteria Database (RDoCdb) [Internet]. Available from: http://rdocdb.nimh.nih.gov/about/

  239. Ekhtiari H, Zare-Bidoky M, Sangchooli A, Janes AC, Kaufman MJ, Oliver JA, et al. A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nat Protoc. 2022;17(3):567–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  240. Klapwijk ET, van den Bos W, Tamnes CK, Raschle NM, Mills KL. Opportunities for increased reproducibility and replicability of developmental neuroimaging. Dev Cogn Neurosci. 2021;47:100902.

    Article  PubMed  Google Scholar 

  241. Heinrichs HS, Beyer F, Medawar E, Prehn K, Ordemann J, Floel A, et al. Effects of bariatric surgery on functional connectivity of the reward and default mode network: a pre-registered analysis. Hum Brain Mapp. 2021;42(16):5357–73.

    Article  PubMed  PubMed Central  Google Scholar 

  242. Weiss F, Zhang J, Aslan A, Kirsch P, Gerchen MF. Feasibility of training the dorsolateral prefrontal-striatal network by real-time fMRI neurofeedback. Sci Rep. 2022;12(1):1669.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, et al. Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder. Int J Neuropsychopharmacol. 2019;22(1):10–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pennington Biomedical Research Center, Baton Rouge, LA, USA

    Owen Carmichael

Authors
  1. Owen Carmichael
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Owen Carmichael .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA

    Matthew Macaluso

  2. Department of Psychiatry and Behavioral Science, Kansas University School of Medicine-Wichita campus, Wichita, KS, USA

    Sheldon H. Preskorn

  3. Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA

    Richard C. Shelton

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Carmichael, O. (2023). The Role of fMRI in Drug Development: An Update. In: Macaluso, M., Preskorn, S.H., Shelton, R.C. (eds) Drug Development in Psychiatry. Advances in Neurobiology, vol 30. Springer, Cham. https://doi.org/10.1007/978-3-031-21054-9_13

Download citation

Publish with us

Policies and ethics

Search

Navigation